Squarepoint
JSPR icon

Squarepoint’s Jasper Therapeutics JSPR Stock Holding History

Squarepoint’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$56.9K Sell
64,915
-217,011
-77% -$301K ﹤0.01% 4129
2025
Q4 		$516K Buy
281,926
+267,966
+1,920% +$538K ﹤0.01% 3196
2025
Q3 		$33.2K Sell
13,960
-11,419
-45% -$34.6K ﹤0.01% 4260
2025
Q2 		$141K Buy
+25,379
New +$125K ﹤0.01% 4079
2023
Q2 		– Sell
-13,989
Closed -$253K – 3791
2023
Q1 		$253K Buy
+13,989
New +$259K ﹤0.01% 2666

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Squarepoint's JSPR Position: Q1 2026 in Review

Squarepoint reduced its Jasper Therapeutics (JSPR) stake by 77% in Q1 2026, selling an estimated $301K and leaving 64,915 shares worth $56.9K. The position accounts for ﹤0.01% of the portfolio, ranked #4129.

Squarepoint first reported a position in JSPR in Q1 2023 and has held it in 5 quarters since. The position peaked at $516K in Q4 2025. 58 funds tracked by Wall St. Rank hold JSPR as of Q1 2026.

  • Squarepoint held 64,915 shares of Jasper Therapeutics worth $56.9K as of Q1 2026.
  • Squarepoint sold 217,011 Jasper Therapeutics shares in Q1 2026, an estimated $301K.
  • Jasper Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #4129 holding.
  • Squarepoint first reported a position in Jasper Therapeutics in Q1 2023 and has held it in 5 quarters since.
  • Squarepoint's Jasper Therapeutics position peaked at $516K in Q4 2025.
  • 58 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.